Results 31 to 40 of about 37,267 (288)

A case of amyloid light amyloidosis involving multiorgan with hepatomegaly as the main manifestation [PDF]

Yixue xinzhi zazhi, 2023
Amyloid light (AL) amyloidosis, also known as primary systemic amyloidosis, is a protein conformation disease, and is a clinical syndrome of functional failure of affected organs due to abnormal folding and deposition of insoluble fibrin in the ...
Ya-Nan CHEN, Jia-Long LIU, Yi-Zhang LI, Ji-Xia ZHANG, Xian-Yan SHI, Jing LIU   +5 more
doaj   +1 more source

Duodenal biopsy: an unexpected confirmatory test for a patient with al-amyloidosis

Sri Lanka Journal of Medicine, 2019
SSystemic AL- amyloidosis is a disorder of protein folding in which there is extra-cellular accumulation as β pleated fibrillar deposits of monoclonal immunoglobulin light chain fragments. AL- amyloidosis is a rare clinical entity.
S. Pirasath, T. Kumanan, G. Selvaratnam, V. Sujanitha, D. D. Dikowita   +4 more
doaj   +1 more source

Incidence and clinical outcome of renal amyloidosis: A retrospective study

Saudi Journal of Kidney Diseases and Transplantation, 2013
The kidneys are affected in almost all patients with amyloid A in secondary amyloidosis (AA) amyloidosis but less frequently in immunoglobulin light chains in primary systemic amyloidosis (AL) amyloidosis.
Emad Abdallah, Emam Waked
doaj   +1 more source

Suggestive Diagnostic Process in a Case of Multiple Myeloma with Gastrointestinal Immunoglobulin Light-Chain Amyloidosis Accompanied by Protein-Losing Enteropathy

Case Reports in Gastrointestinal Medicine, 2021
Multiple myeloma is a type of plasma cell neoplasm that produces monoclonal immunoglobulin. Multiple myeloma is known to cause immunoglobulin light-chain (AL) amyloidosis, which frequently involves the kidney and heart.
Katsuya Endo, Takehito Ito, Jun Nomura, Keigo Murakami, Shiho Kondo, Tomonori Satoh, Daisuke Fukushi, Yuki Yoshino, Yoshiteru Sasaki, Atsuko Takasu, Takayuki Kogure, Morihisa Hirota, Takayoshi Meguro, Kazuhiro Murakami, Junichi Kameoka, Kennichi Satoh   +15 more
doaj   +1 more source

Effects of Amyloid Light-Chain Amyloidosis on Clinical Characteristics and Prognosis in Multiple Myeloma: A Single-Center Retrospective Study

Cancer Management and Research, 2021
Junhui Xu,* Mangju Wang,* Ye Shen, Miao Yan, Weiwei Xie, Bingjie Wang, Huihui Liu, Xinan Cen Department of Hematology, Peking University First Hospital, Beijing, People’s Republic of China*These authors contributed equally to this ...
Xu J, Wang M, Shen Y, Yan M, Xie W, Wang B, Liu H, Cen X   +7 more
doaj  

Hemostasis disorders in patients with systemic AL-amyloidosis

Терапевтический архив, 2023
Aim. To analyze the frequency and nature of hemorrhagic and thrombotic complications in patients with systemic AL-amyloidosis and compare with laboratory changes in the hemostasis system. Materials and methods.
Irina G. Rekhtina, Victoria A. Khyshova, Nadezhda I. Zozulya, Valentina N. Dvirnyk, Larisa P. Mendeleyeva   +4 more
doaj   +1 more source

First third-generation CAR T cell application targeting CD19 for the treatment of systemic IgM AL amyloidosis with underlying marginal zone lymphoma

Biomarker Research, 2023
Light chain amyloidosis (AL) is a rare disease caused by the generalized deposition of misfolded free light chains. Patients with immunoglobulin M gammopathy (IgM) and indolent B-cell lymphoma such as marginal zone lymphoma (MZL) may in some instances ...
Felix Korell, Stefan Schönland, Anita Schmitt, Madelaine Jansen, Kiavasch Farid, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt, Ute Hegenbart   +8 more
doaj   +1 more source

A bibliometric analysis of light chain amyloidosis from 2005 to 2024: research trends and hot spots

Frontiers in Medicine
BackgroundLight chain (AL) amyloidosis stands as the most prevalent subtype of systemic amyloidosis, encompassing a group of rare diseases. Here, we evaluated the scientific landscape of AL amyloidosis to investigate research trends and identify hotspots
Xiangdong Liu, Xiangdong Liu, Junyan Wang, Junyan Wang, Yingmin Li, Yingmin Li, Yingmin Li, Weibo Shi, Weibo Shi, Weibo Shi, Xiaojing Zhang, Xiaojing Zhang, Xiaojing Zhang, Shujin Li, Shujin Li, Shujin Li, Bin Cong, Bin Cong, Bin Cong, Bin Cong   +19 more
doaj   +1 more source

Alterations of the gut microbiota in patients with immunoglobulin light chain amyloidosis

Frontiers in Immunology, 2022
BackgroundEmerging evidence revealed that gut microbial dysbiosis is implicated in the development of plasma cell dyscrasias and amyloid deposition diseases, but no data are available on the relationship between gut microbiota and immunoglobulin light ...
Jipeng Yan, Jin Zhao, Xiaoxuan Ning, Yunlong Qin, Yan Xing, Yuwei Wang, Qing Jia, Boyong Huang, Rui Ma, Changhui Lei, Meilan Zhou, Zixian Yu, Yumeng Zhang, Wei-Feng Guo, Wei-Feng Guo, Shiren Sun   +15 more
doaj   +1 more source

Daratumumab for the treatment of AL amyloidosis [PDF]

Leukemia & Lymphoma, 2018
Autologous stem cell transplantation (ASCT) has been used as treatment for immunoglobulin light-chain (AL) amyloidosis for over two decades with improving outcomes; however, the majority of patients are not candidates for this therapy at diagnosis. Novel agents such as immunomodulatory drugs, proteasome inhibitors, and immunotherapy with monoclonal ...
M. Hasib Sidiqi, Morie A. Gertz
openaire   +3 more sources